Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
81.1M
-
Number of holders
-
135
-
Total 13F shares, excl. options
-
71M
-
Shares change
-
+10.6M
-
Total reported value, excl. options
-
$1.24B
-
Value change
-
+$176M
-
Put/Call ratio
-
2.21
-
Number of buys
-
82
-
Number of sells
-
-52
-
Price
-
$17.51
Significant Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN) as of Q1 2024
165 filings reported holding VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share as of Q1 2024.
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN) has 135 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 71M shares
of 81.1M outstanding shares and own 87.5% of the company stock.
Largest 10 shareholders include FMR LLC (9.42M shares), Paradigm Biocapital Advisors LP (5.03M shares), STATE STREET CORP (4.49M shares), VR Adviser, LLC (3.88M shares), BlackRock Inc. (3.81M shares), PERCEPTIVE ADVISORS LLC (3.66M shares), Deep Track Capital, LP (3.46M shares), VANGUARD GROUP INC (3.23M shares), MAVERICK CAPITAL LTD (2.69M shares), and COMMODORE CAPITAL LP (1.93M shares).
This table shows the top 135 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.